Discover trends, market shifts, and competitive outlooks for the myelodysplastic syndrome industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Myelodysplastic Syndrome Market, and What Factors Will Drive It?

In recent times, there has been a substantial expansion of the myelodysplastic syndrome market. The market, which is projected to grow from a value of $2.56 billion in 2024 to $2.85 billion in 2025, will do so at a compound annual growth rate (CAGR) of 11.3%. The impressive growth seen in the historical period can be traced back to factors like an enhanced understanding of myelodysplastic syndrome treatments, increased healthcare expenditure, government policies, and a rise in the number of myelodysplastic syndrome cases.

We anticipate robust expansion in the myelodysplastic syndrome market size in the coming years. The value is predicted to reach $4.17 billion by 2029, with a compound annual growth rate (CAGR) of 10.0%. The positive growth in the projected period can be linked to an aging population, the embracing of combination therapies, financial contributions to hematologic studies, and tailored medical treatments. The forecast period is set to usher in key trends such as novel treatments for myelodysplastic syndrome, advancements in diagnostic tools and methods, clinical trials, and cooperative research.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12920&type=smp

Which Primay Drivers Are Accelerating Growth in the Myelodysplastic Syndrome Market?

The rising occurrences of rare types of blood cancers are anticipated to fuel the expansion of the myelodysplastic syndrome (MDS) market. Blood cancers, which originate from bone marrow cells, lymph nodes, and other elements of the blood and immune system, have a low prevalence in the population and are considered hematologic malignancies. Treatment for MDS focuses on managing the illness by enhancing the production of blood cells and addressing related symptoms to hinder blood cancer progression in the bone marrow. For instance, the Leukemia and Lymphoma Society shared in September 2024 that, in the United States, a person is diagnosed with leukemia, lymphoma, or myeloma every three minutes. In 2024, they estimate that 187,740 people will experience these cancers, which is about 9.4% of the projected 2,001,140 new cancer cases in the US. As a result, the escalating rate of blood cancer is propelling the growth of the MDS market. Looking ahead to the future of the Myelodysplastic Syndrome Market, one key driver is the anticipated increase in bone marrow transplants. Bone marrow transplantation is a medical procedure that replaces diseased or damaged bone marrow with healthy stem cells, offering a potential cure for varying conditions. In MDS cases, the illness is characterized by bone marrow failure due to the selective growth of clonally changed somatic hematopoietic stem cells. Bone marrow transplants provide a solution to MDS by replacing these defective stem cells with normal ones. For example, according to the National Transplant Organization (ONT) – an independent coordinating agency based in Spain – in 2023, Spain added 23,686 donors to their Bone Marrow Donor Registry, marking an 8% increase from 2022, and completed a record-breaking 3,717 hematopoietic stem cell transplants, or 77.4 transplants per million people. Therefore, the expected increase in the number of bone marrow transplants is fueling the expansion of the MDS market.

Which Primary Segments of the Myelodysplastic Syndrome Market Are Driving Growth and Industry Transformations?

The myelodysplastic syndrome market covered in this report is segmented –

1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia, Myelodysplastic Syndrome With Multilineage Dysplasia, Myelodysplastic Syndrome With Ring Sideroblasts, Other Types

2) By Drug: Azacitidine, Lenalidomide, Decitabine, Deferasirox

3) By Treatment: Supportive Therapy, Growth Factors, Chemotherapy, Stem Cell Transplant, Other Treatments

4) By Route Of Administration: Oral, Injectable, Other Routes Of Administrations

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Myelodysplastic Syndrome With Unilineage Dysplasia: Type Of Dysplasia, Patient Demographics

2) By Myelodysplastic Syndrome With Multilineage Dysplasia: Severity Of Dysplasia, Patient Demographics

3) By Myelodysplastic Syndrome With Ring Sideroblasts: Percentage Of Ring Sideroblasts, Treatment Options

4) By Other Types: Specific Types, Treatment Options

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12920&type=smp

Which Regions Are Key Players in the Growth of the Myelodysplastic Syndrome Market?

North America was the largest region in the myelodysplastic syndrome market in 2024. The regions covered in myelodysplastic syndrome (MDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Myelodysplastic Syndrome Industry Dynamics?

Prominent companies active in the Myelodysplastic Syndrome (MDS) market are evolving new therapies to bolster their market dominance. For example, in August 2023, United States-based pharmaceutical giant Bristol Myers Squibb earned the approval of the FDA for Reblozyl (luspatercept-aamt), positioning it as a primary treatment for anemia in ESA-naïve adults diagnosed with low- to intermediate-risk Myelodysplastic Syndromes (MDS), who may require frequent RBC transfusions. The Phase 3 COMMANDS trial revealed that Reblozyl outperformed epoetin alfa in accomplishing RBC transfusion independence and elevated hemoglobin levels, thereby addressing anemia earlier and in a wider patient population.

View the full report here:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

What Parameters Are Used to Define the Myelodysplastic Syndrome Market?

Myelodysplastic syndrome (MDS) is a group of disorders characterized by the malfunctioning or abnormal development of bone marrow cells, leading to ineffective blood cell production. Myelodysplastic syndrome treatment improves blood cell counts, alleviates symptoms and delays disease progression. Myelodysplastic syndrome (MDS) can progress to acute myeloid leukemia (AML), a more aggressive form of blood cancer.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12920

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model